Free Trial
NASDAQ:LGND

Ligand Pharmaceuticals (LGND) Stock Price, News & Analysis

Ligand Pharmaceuticals logo
$122.40 +7.28 (+6.32%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$122.39 -0.01 (-0.01%)
As of 07/9/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Ligand Pharmaceuticals Stock (NASDAQ:LGND)

Key Stats

Today's Range
$116.44
$124.62
50-Day Range
$100.19
$122.40
52-Week Range
$90.29
$129.90
Volume
194,021 shs
Average Volume
117,581 shs
Market Capitalization
$2.36 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$147.17
Consensus Rating
Buy

Company Overview

Ligand Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
88th Percentile Overall Score

LGND MarketRank™: 

Ligand Pharmaceuticals scored higher than 88% of companies evaluated by MarketBeat, and ranked 58th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Ligand Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Ligand Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about Ligand Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Ligand Pharmaceuticals are expected to grow by 114.45% in the coming year, from $1.73 to $3.71 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Ligand Pharmaceuticals is -17.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Ligand Pharmaceuticals is -17.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Ligand Pharmaceuticals has a P/B Ratio of 2.78. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Ligand Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    6.41% of the float of Ligand Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Ligand Pharmaceuticals has a short interest ratio ("days to cover") of 9.7.
  • Change versus previous month

    Short interest in Ligand Pharmaceuticals has recently decreased by 6.50%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Ligand Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Ligand Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.41% of the float of Ligand Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Ligand Pharmaceuticals has a short interest ratio ("days to cover") of 9.7.
  • Change versus previous month

    Short interest in Ligand Pharmaceuticals has recently decreased by 6.50%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Ligand Pharmaceuticals has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Ligand Pharmaceuticals this week, compared to 6 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Ligand Pharmaceuticals insiders have bought 429.77% more of their company's stock than they have sold. Specifically, they have bought $1,156,542.00 in company stock and sold $218,310.00 in company stock.

  • Percentage Held by Insiders

    Only 7.00% of the stock of Ligand Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    91.28% of the stock of Ligand Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Ligand Pharmaceuticals' insider trading history.
Receive LGND Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

LGND Stock News Headlines

A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Headlines

LGND Stock Analysis - Frequently Asked Questions

Ligand Pharmaceuticals' stock was trading at $107.15 at the start of the year. Since then, LGND shares have increased by 14.2% and is now trading at $122.40.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) issued its quarterly earnings data on Thursday, May, 8th. The biotechnology company reported $1.33 EPS for the quarter, beating the consensus estimate of $1.23 by $0.10. The biotechnology company had revenue of $45.33 million for the quarter, compared to analysts' expectations of $37.84 million. Ligand Pharmaceuticals had a negative net margin of 73.07% and a negative trailing twelve-month return on equity of 7.83%.
Read the conference call transcript
.

Top institutional shareholders of Ligand Pharmaceuticals include Woodstock Corp (0.15%). Insiders that own company stock include John L Higgins, Todd C Davis, Matthew E Korenberg, John W Kozarich, Andrew Reardon, John L Lamattina, Stephen L Sabba, Octavio Espinoza and Nancy Ryan Gray.
View institutional ownership trends
.

Shares of LGND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Ligand Pharmaceuticals investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
5/08/2025
Today
7/09/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:LGND
CIK
886163
Employees
80
Year Founded
N/A

Price Target and Rating

High Price Target
$160.00
Low Price Target
$135.00
Potential Upside/Downside
+20.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
70.75
P/E Growth
N/A
Net Income
-$4.03 million
Pretax Margin
-88.77%

Debt

Sales & Book Value

Annual Sales
$167.13 million
Cash Flow
$1.73 per share
Price / Cash Flow
70.80
Book Value
$43.95 per share
Price / Book
2.78

Miscellaneous

Free Float
17,943,000
Market Cap
$2.36 billion
Optionable
Optionable
Beta
0.84

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:LGND) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners